SEC Company Response from Altimmune, Inc. (ALT) (CIK 0001326190) (ALT) — Apr 6, 2017
Altimmune, Inc. (ALT) (CIK 0001326190)
Date: April 6, 2017 · CIK: 0001326190 · Accession: 0001144204-17-019330
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-217034
Letter
Re:
April 6, 2017
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
PharmAthene, Inc.
Registration Statement on Form S-3
File No. 333-217034
Acceleration Request
Requested Date: April 6,
Requested Time: 5:00 pm Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, PharmAthene, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 be accelerated so that the Registration Statement may become effective at the “Requested Date” and “Requested Time” set forth above, or at such later time as the Registrant or its counsel, Dentons US LLP, may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Please call Jeffrey A. Baumel of Dentons US LLP at (973) 912-7189 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
PHARMATHENE, INC.
Show Raw Text
CORRESP
1
filename1.htm
April 6, 2017
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Re:
PharmAthene, Inc.
Registration Statement on Form S-3
File No. 333-217034
Acceleration Request
Requested Date: April 6,
2017
Requested Time: 5:00 pm Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461
under the Securities Act of 1933, as amended, PharmAthene, Inc. (the “Registrant”) hereby requests that the effective
date of the above-referenced Registration Statement on Form S-3 be accelerated so that the Registration Statement may become effective
at the “Requested Date” and “Requested Time” set forth above, or at such later time as the Registrant or
its counsel, Dentons US LLP, may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities
and Exchange Commission.
Please call Jeffrey A. Baumel of Dentons
US LLP at (973) 912-7189 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
PHARMATHENE, INC.
/s/ Philip MacNeill
Philip MacNeill
Vice President, Chief Financial Officer,
Treasurer and Secretary
cc: Jeffrey A. Baumel, Dentons US LLP